Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Drug Safety Research Project Planned in the U.K.

By University of Liverpool | January 30, 2017

Liverpool to coordinate £14M drug safety research project.

The University of Liverpool (UK) is to co-ordinate a new £14 million ($17.5 million) European research project which aims to improve the understanding of adverse drug reactions by using cutting-edge modeling approaches to drug safety.

Adverse drug reactions (ADRs) are the unwanted side effects of medication. They can contribute significantly to patient morbidity, mortality and hospitalization costs.

Funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) the five-year project, called Translational Quantitative Systems Toxicology to Improve the Understanding of the Safety of Medicines (TransQST), aims to develop novel approaches using the best available data from the public and private domains to address the problems of drug safety.

Partnership

One of the main focuses of the project are ‘off-target reactions’ which cannot be predicted from the known pharmacological properties of the drug. The main organs of concern for such reactions are the liver, the kidney and the cardiovascular and gastrointestinal systems.

TransQST is a partnership between ten academic institutions, three Small and Medium-sized enterprises (SMEs) and eight pharmaceutical companies, with a total budget of £14 million. The project will be coordinated by the University of Liverpool, and the pharmaceutical company AbbVie is the Project Leader.

IMI2 is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI2 supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Safe Drug Development

Project co-coordinator Professor Kevin Park from the University’s Institute of Translational Medicine, said: “The fear of ADRs is a major impediment to the development of new, safe and effective therapies.

“This project will enable us to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help to address the problems of safe drug development.

“Our ultimate aim is to maximize the benefits of medicines and minimize the harm.”

The focus of the TransQST project will be to provide innovative methodologies and software tools for systems toxicology modeling.

The TransQST project will: 

  • Provide fit-for-purpose QST models addressing key toxicity outcomes for liver, kidney, heart and GI-tract.
  • Provide quantitative risk assessment for off-target toxicities in man based on in vitro and in vivo models.
  • Provide a quantitative mechanistic read-across from species (in vitro and in vivo) currently used for the toxicological evaluation of a new drug.
  • Provide definition and applicability of the human physiological and pharmacological relevance of preclinical test systems.
  • Provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man, and which relate to intracellular pathways (and systems) relevant to drug toxicity.

The TransQST partners are:

1. University of Liverpool 
2. Unversiteit Leiden 
3. Fundació Institut Mar d’Investigacions Mèdiques (IMIM) 
4. Synapse Research Management Partners SL 
5. Universiteit Maastricht 
6. European Molecular Biology Laboratory 
7. The Chancellor, Masters and Scholars of the University of Oxford 
8. Simcyp Limited 
9. Universität Wien 
10. Universitätsklinikum Aachen 
11. Forchungsgesellschaft für Arbetisphysiologie und Arbeitsschutz e.V. 
12. OcellO B.V. 
13. Erasmus Universitair Medisch Centrum Rotterdam 
14. AbbVie Deutschland GmbH & Co. KG 
15. Eli Lilly and Company Ltd 
16. Sanofi-Aventis Recherche & Développement 
17. AstraZeneca AB 
18. Glaxosmithkline Research and Development LTD 
19. Institut de Recherches Internationales Servier 
20. Janssen Pharmaceutica NV 
21. Orion Corporation

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50